Clinica Chimica Acta:dolichol isoform profile在CDG疾病诊断中的新作用

2020-06-22 MedSci原创 MedSci原创

Dolichol是一种膜脂质,它携带单糖和多糖,内质网上发生n -连锁蛋白糖基化反应。

Dolichol是一种膜脂质,它携带单糖和多糖,内质网上发生n -连锁蛋白糖基化反应。近年来,一些类型的糖基化(CDG)先天性疾病被描述为多尔科尔生物合成和代谢缺陷的后果,但这些类型的CDG无法通过标准的筛选方法检测出来。本项目的目的是评估dolichol作为CDG生物标志物的潜力。

本研究的生物材料包括来自75名对照者、6名CDG患者和43名怀疑CDG患者的尿液样本;2例NUS1基因突变患者的额叶皮层、肝脏、肌肉和心脏组织的样本和对照组。采用液相色谱-串联质谱联用技术对多力高的分子物种进行了分析。

在对照组中,尿中dolichol 18与dolichol 19的比值(Dol18/Dol19)与年龄显著相关。我们从尿液样本中建立了Dol18/Dol19的参考范围。与对照组相比,NUS1突变患者的尿液和组织样本中Dol18/Dol19的比值均显著高于对照组。我们的结果显示了一种新的诊断选择的患者罕见的先天性疾病的糖基化。

原始出处:

L.ZdrazilovaL.KucharN.OndruskovaA new role for dolichol isoform profile in the diagnostics of CDG disorders

评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1688680, encodeId=ecc31688680af, content=<a href='/topic/show?id=7dc0e0725aa' target=_blank style='color:#2F92EE;'>#疾病诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70725, encryptionId=7dc0e0725aa, topicName=疾病诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e21828610836, createdName=zywlvao, createdTime=Sun May 23 04:12:04 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924145, encodeId=da681924145f7, content=<a href='/topic/show?id=794d5803930' target=_blank style='color:#2F92EE;'>#新作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58039, encryptionId=794d5803930, topicName=新作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24a22500182, createdName=1696533704_45270454, createdTime=Mon Sep 28 04:12:04 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791495, encodeId=524d1e914952c, content=<a href='/topic/show?id=11dc14e11b6' target=_blank style='color:#2F92EE;'>#Profile#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14711, encryptionId=11dc14e11b6, topicName=Profile)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Thu Mar 25 01:12:04 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849943, encodeId=803f184994364, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Mar 07 12:12:04 CST 2021, time=2021-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316381, encodeId=cd08131638135, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9349, encryptionId=f3789349c3, topicName=ICH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Wed Jun 24 14:12:04 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602278, encodeId=b8ac16022e858, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Jun 24 14:12:04 CST 2020, time=2020-06-24, status=1, ipAttribution=)]
    2021-05-23 zywlvao
  2. [GetPortalCommentsPageByObjectIdResponse(id=1688680, encodeId=ecc31688680af, content=<a href='/topic/show?id=7dc0e0725aa' target=_blank style='color:#2F92EE;'>#疾病诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70725, encryptionId=7dc0e0725aa, topicName=疾病诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e21828610836, createdName=zywlvao, createdTime=Sun May 23 04:12:04 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924145, encodeId=da681924145f7, content=<a href='/topic/show?id=794d5803930' target=_blank style='color:#2F92EE;'>#新作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58039, encryptionId=794d5803930, topicName=新作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24a22500182, createdName=1696533704_45270454, createdTime=Mon Sep 28 04:12:04 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791495, encodeId=524d1e914952c, content=<a href='/topic/show?id=11dc14e11b6' target=_blank style='color:#2F92EE;'>#Profile#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14711, encryptionId=11dc14e11b6, topicName=Profile)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Thu Mar 25 01:12:04 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849943, encodeId=803f184994364, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Mar 07 12:12:04 CST 2021, time=2021-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316381, encodeId=cd08131638135, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9349, encryptionId=f3789349c3, topicName=ICH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Wed Jun 24 14:12:04 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602278, encodeId=b8ac16022e858, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Jun 24 14:12:04 CST 2020, time=2020-06-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1688680, encodeId=ecc31688680af, content=<a href='/topic/show?id=7dc0e0725aa' target=_blank style='color:#2F92EE;'>#疾病诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70725, encryptionId=7dc0e0725aa, topicName=疾病诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e21828610836, createdName=zywlvao, createdTime=Sun May 23 04:12:04 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924145, encodeId=da681924145f7, content=<a href='/topic/show?id=794d5803930' target=_blank style='color:#2F92EE;'>#新作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58039, encryptionId=794d5803930, topicName=新作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24a22500182, createdName=1696533704_45270454, createdTime=Mon Sep 28 04:12:04 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791495, encodeId=524d1e914952c, content=<a href='/topic/show?id=11dc14e11b6' target=_blank style='color:#2F92EE;'>#Profile#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14711, encryptionId=11dc14e11b6, topicName=Profile)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Thu Mar 25 01:12:04 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849943, encodeId=803f184994364, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Mar 07 12:12:04 CST 2021, time=2021-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316381, encodeId=cd08131638135, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9349, encryptionId=f3789349c3, topicName=ICH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Wed Jun 24 14:12:04 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602278, encodeId=b8ac16022e858, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Jun 24 14:12:04 CST 2020, time=2020-06-24, status=1, ipAttribution=)]
    2021-03-25 hunizi005

    #Profile#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1688680, encodeId=ecc31688680af, content=<a href='/topic/show?id=7dc0e0725aa' target=_blank style='color:#2F92EE;'>#疾病诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70725, encryptionId=7dc0e0725aa, topicName=疾病诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e21828610836, createdName=zywlvao, createdTime=Sun May 23 04:12:04 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924145, encodeId=da681924145f7, content=<a href='/topic/show?id=794d5803930' target=_blank style='color:#2F92EE;'>#新作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58039, encryptionId=794d5803930, topicName=新作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24a22500182, createdName=1696533704_45270454, createdTime=Mon Sep 28 04:12:04 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791495, encodeId=524d1e914952c, content=<a href='/topic/show?id=11dc14e11b6' target=_blank style='color:#2F92EE;'>#Profile#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14711, encryptionId=11dc14e11b6, topicName=Profile)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Thu Mar 25 01:12:04 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849943, encodeId=803f184994364, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Mar 07 12:12:04 CST 2021, time=2021-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316381, encodeId=cd08131638135, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9349, encryptionId=f3789349c3, topicName=ICH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Wed Jun 24 14:12:04 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602278, encodeId=b8ac16022e858, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Jun 24 14:12:04 CST 2020, time=2020-06-24, status=1, ipAttribution=)]
    2021-03-07 windight

    #CTA#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1688680, encodeId=ecc31688680af, content=<a href='/topic/show?id=7dc0e0725aa' target=_blank style='color:#2F92EE;'>#疾病诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70725, encryptionId=7dc0e0725aa, topicName=疾病诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e21828610836, createdName=zywlvao, createdTime=Sun May 23 04:12:04 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924145, encodeId=da681924145f7, content=<a href='/topic/show?id=794d5803930' target=_blank style='color:#2F92EE;'>#新作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58039, encryptionId=794d5803930, topicName=新作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24a22500182, createdName=1696533704_45270454, createdTime=Mon Sep 28 04:12:04 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791495, encodeId=524d1e914952c, content=<a href='/topic/show?id=11dc14e11b6' target=_blank style='color:#2F92EE;'>#Profile#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14711, encryptionId=11dc14e11b6, topicName=Profile)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Thu Mar 25 01:12:04 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849943, encodeId=803f184994364, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Mar 07 12:12:04 CST 2021, time=2021-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316381, encodeId=cd08131638135, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9349, encryptionId=f3789349c3, topicName=ICH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Wed Jun 24 14:12:04 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602278, encodeId=b8ac16022e858, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Jun 24 14:12:04 CST 2020, time=2020-06-24, status=1, ipAttribution=)]
    2020-06-24 diushouji

    #ICH#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1688680, encodeId=ecc31688680af, content=<a href='/topic/show?id=7dc0e0725aa' target=_blank style='color:#2F92EE;'>#疾病诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70725, encryptionId=7dc0e0725aa, topicName=疾病诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e21828610836, createdName=zywlvao, createdTime=Sun May 23 04:12:04 CST 2021, time=2021-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924145, encodeId=da681924145f7, content=<a href='/topic/show?id=794d5803930' target=_blank style='color:#2F92EE;'>#新作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58039, encryptionId=794d5803930, topicName=新作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24a22500182, createdName=1696533704_45270454, createdTime=Mon Sep 28 04:12:04 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791495, encodeId=524d1e914952c, content=<a href='/topic/show?id=11dc14e11b6' target=_blank style='color:#2F92EE;'>#Profile#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14711, encryptionId=11dc14e11b6, topicName=Profile)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49ef408, createdName=hunizi005, createdTime=Thu Mar 25 01:12:04 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849943, encodeId=803f184994364, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Mar 07 12:12:04 CST 2021, time=2021-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1316381, encodeId=cd08131638135, content=<a href='/topic/show?id=f3789349c3' target=_blank style='color:#2F92EE;'>#ICH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9349, encryptionId=f3789349c3, topicName=ICH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Wed Jun 24 14:12:04 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602278, encodeId=b8ac16022e858, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Jun 24 14:12:04 CST 2020, time=2020-06-24, status=1, ipAttribution=)]
    2020-06-24 sunylz

    #PRO#

    0